Cancer
is essentially the uncontrolled growth of certain cells in the body
that crowd out normal cells over time. When cells in the breast begin
to grow out of control it may lead to breast cancer. These cells
generally form a tumor that can felt as a lump, which can further be
confirmed using a mammogram. The tumor is malignant if the cells can
grow into surrounding tissues or spread to other parts of the body.
Breast
cancer occurs almost entirely in women, though men can
also contract breast cancer. Mutations in DNA can cause normal breast
cells to become cancerous cells. Some DNA changes are passed on from
parents and can significantly increase the threat for breast cancer.
Moreover, lifestyle related risk factors such as consumption of fast
food and lack of exercise can increase chances of developing breast
cancer. However, the exact cause of the disease is yet unknown.
According
to Breast Cancer Organization, an estimated 252,710 new cases of
breast cancer are expected to be identified in the U.S., of which
63,410 cases would be non-invasive breast cancer in 2017. In the
U.S., breast cancer death rates are higher than those for any other
cancer, besides lung cancer among women. Breast cancer is especially
prevalent among women under 45 years of age and African American
women rather than white women.
Download
PDF Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/250
Increasing
occurrence of the disease especially in the Developed countries will
drive growth of the breast cancer therapeutics market
According
to World Health Organization statistics, breast cancer is the
second-most predominant type (whereas lung cancer is first) of the
disease globally, and the most common type in females. In women, this
type of cancer accounts for 20% of all invasive and 13% of all female
cancers, and is responsible for 15% of deaths caused by the disease
globally, including females and males. Every year, around 200,000 new
cases in women and approximately 2,000 new cases are diagnosed in
men. The incidence of breast cancer remained steady in white women
and increased to some extent (less than 1% year) in African American
women. Epidemiologists predict that the established incident cases of
breast cancer in women will grow by over the following decade to
reach 949,161 cases in 2025. This rise in demand will ultimately push
the global breast cancer therapeutics market into a positive growth
curve over the course of the forecast period.
Breast
Cancer Therapeutics Market:
On
the basis of type of drug class, the global market is classified
into:
•
HER2 Inhibitors
•
Mitotic Inhibitors
•
Anti-metabolites
•
Aromatase Inhibitors
•
Hormone Receptor Agonist/Antagonist
Globally
breast cancer is the most common cancer in women, with a prevalence
of around 1.7 million in 2012, the second-most common cancer overall.
This represents 12% of all new cancer cases and 25% of all cancers in
women. Belgium had the topmost rate of breast cancer, followed by
Denmark and France, respectively. Marginally less number of cases of
breast cancer were diagnosed in less developed countries. The highest
occurrence of this type of cancer was in Northern America and
Oceania, whereas the lowest incidence rate in Asia and Africa.
Get
Discount on This Exclusive Research Report @
https://www.coherentmarketinsights.com/insight/request-discount/250
Breast
Cancer Therapeutics Market - Key Players
Key
players operating in the global breast cancer therapeutics market are
-
AstraZeneca plc
-
Eli Lilly and Company
-
Eisai Co., Ltd.
-
F. Hoffmann-La Roche AG
-
GlaxoSmithKline plc
-
Pfizer, Inc.
-
Novartis International AG
-
Puma Biotechnology
-
Sanofi S.A.
-
Teva Pharmaceutical Industries
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment